Researchers have shed new light on the most common genetic variant linked to hereditary cancer in Quebec’s French-Canadian population. Their findings could result in cheaper and more effective screening methods.
The variant is associated with Lynch syndrome, a condition that greatly increases the risk of colorectal and other cancers.
The federal government is expected to overhaul Canada’s cancer screening task force following criticism that its recommendations are outdated and lacked expert input. Breast cancer screening is a key focus, with growing pressure to lower the starting age to 40.
McGill University experts are available to speak to the debate, including:
A new study demonstrates how universal genetic testing for breast cancer can ensure no patient is missed for advanced therapies.
Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare and one common form.
Screening for genes whose risk association with breast cancer has yet to be proven is not justified and potentially harmful, argue an international team of leading geneticists and oncologists in a paper published this week in the prestigious New England Journal of Medicine.
